Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BEECHAM's ANEXSIA-D TAB HYDROCODONE BITARTRATE COMBO

Executive Summary

BEECHAM's ANEXSIA-D TAB HYDROCODONE BITARTRATE COMBO is one of nine products in that class of combo drugs getting close FDA scrutiny. A recent memo from FDA's drug labeling compliance division to the agency's field offices lists 12 hydrocodone combo products without approved ANDAs. The compliance office is asking the field force to visit 12 firms to "document the current marketing status" of those products. "If a firm has received a Regulatory Letter and response is unsatisfactory," the FDA memo says, "obtain a sample of each product listed, for a seizure action." A footnote to the list of hydrocodone bitartrate combos without ANDAs indicates that Beecham has received a regulatory letter about the product and had not submitted a satisfactory response as of March 7. The compliance office noted that some of the firms identified on the list for close attention by the field have submitted ANDAs and/or have petitioned for suitability of an ANDA "but the ANDA's are not as yet approved, nor can we at this time forecast if/or when they will be approved." HYDROCODONE BITARTRATE PRODUCTS TO RECEIVE CLOSE FDA FIELD SCRUTINY Amid Labs, Inc. Dolo-Pap Tab (acetaminophen, hydrocodone bitartrate) Anabolic, Inc. Damason-P Tab (aspirin, caffeine, hydrocodone bitartrate) Beecham Labs Anexsia-D Tab (hydrocodone bitartrate, aspirin, phenacetin, caffeine) Berlex Labs, Inc. Anodynos-DHC Tab (aspirin, hydrocodone bitartrate, acetaminophen, hydrocodone) Caldwell & Bloor Diascaphen Tab (aspirin, hydrocodone bitartrate, salicylamide, caffeine) Central Pharmaceutics, Inc. Di-Gesic Tab (acetaminophen, hydrocodone bitartrate, caffeine, aspirin) Luchem Pharm, Inc. Hycomed Tab (hydrocodone bitartrate, acetaminophen) Mason Pharmaceuticals Damason-P Tab (aspirin, caffeine, hydrocodone bitartrate) Pharmedix Damason-P Tab (aspirin, caffeine, hydrocodone bitartrate) Scripotat, Inc. Damason-P Tab (aspirin, caffeine, hydrocodone bitartrate) Shoals Pharmaceutical Company Hycogesic Tab (hydrocodone bitartrate, acetaminophen, aspirin, caffeine) UAD Labs Lorcet Plus Tab (hydrocodone bitartrate 7.5 mg, acetaminophen 650 mg) Lorpac Tab (aspirin, hydrocodone bitartrate, caffeine, acetaminophen)

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS009878

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel